Key Scientific Findings to Be Presented by Diabetes Experts at the
American Diabetes Association Scientific Sessions
LOS ANGELES–(BUSINESS WIRE)–Eyenuk
Inc., a global artificial intelligence (AI) medical technology and
services company and the leader in real-world applications for AI Eye
Screening™, announced today that data from scientific studies related to
the screening efficacy of the EyeArt®
AI Eye Screening System and the impact of using the EyeArt AI System
in improving compliance with follow-up ophthalmic care for diabetic
retinopathy (DR) will be presented during the American Diabetes
Association (ADA) 79th Scientific Sessions from June 7 to 11
in San Francisco.
The EyeArt AI Eye Screening System is the most extensively validated AI
technology for autonomous detection of DR, tested in the real world on
more than a half-million patient visits globally with over 2 million
images collected in real-world clinical environments. In a prospective,
multicenter, pivotal clinical trial, the EyeArt System demonstrated
exceptional performance with 95.5% sensitivity, 86.5% specificity and
97.4% imageability against the rigorous ETDRS clinical reference
standard while meeting all primary endpoints with p<0.0001.1
Currently, physicians treating patients with diabetes must refer them
annually to an eye specialist for DR screening. While DR screening is
recommended for all diabetic patients, less than half get screened
annually. In contrast, the EyeArt AI Eye Screening System is designed to
make in-clinic, real-time DR screening possible for any physician,
enabling quick and accurate on-site identification of patients with DR
during a diabetic patient’s regular exam, removing the biggest obstacles
to annual DR screening and diagnosis: screening access and patient
compliance. AI Eye Screening technology allows diabetes care providers
to identify patients with referable DR in clinic, in real time, without
needing eye care expertise on site, and immediately refer at-risk
patients to ophthalmologists for further evaluation and treatment.
The ADA scientific program will feature multiple scientific
presentations related to the EyeArt AI Eye Screening System:
A late-breaking abstract presented by Bruce Bode, M.D., past president
of the American Diabetes Association Georgia Affiliate: Diabetic
Retinopathy (DR) Screening Performance of an Artificial Intelligence
(AI) System: Analysis from a Pivotal Multicenter Prospective Clinical
Trial. The abstract will be presented from 12–1 p.m. on Sunday,
June 9. Dr. Bode is a diabetes specialist with Atlanta Diabetes
Associates in Atlanta and is currently on the faculty of Emory
University as a clinical associate professor in the Department of
In addition, Eli Ipp, M.D., will present Diabetic Retinopathy (DR)
Screening Performance of General Ophthalmologists, Retina Specialists,
and Artificial Intelligence (AI): Analysis from a Pivotal Multicenter
Prospective Clinical Trial. The abstract will be presented from
12–1 p.m. on Monday, June 10. Dr. Ipp is professor of medicine at the
UCLA School of Medicine, and head of the Section of Diabetes and
Metabolism at Harbor-UCLA Medical Center.
Washington University School of Medicine in St. Louis and the
Department of Ophthalmology will present Automated Diabetic
Retinopathy Screening in the Primary Care Setting Improves Compliance
with Follow-Up Ophthalmic Care. The abstract will be presented on
Monday, June 10, from 12–1 p.m.
Finally, Eyenuk will present Explaining an Artificial Intelligence
(AI) System for Diabetic Retinopathy (DR) Screening in Primary Care
on Monday, June 10, from 12–1 p.m.
“By giving clinicians who treat diabetes the right tools, we can help
them identify DR sooner and get patients treated faster,” said Kaushal
Solanki, Ph.D., founder and CEO of Eyenuk. “The EyeArt AI Eye Screening
System is the solution they need to ensure patient compliance, screen
regularly and save vision. We’re pleased to be a part of this meeting
and share our successful implementation in a number of countries
spanning five continents across the globe.”
Eyenuk will showcase its EyeArt AI Eye Screening System at Booth #2007
in the ADA Exhibit Hall at the Moscone Center in San Francisco. The
company’s management team will be available to meet with clinical and
About the EyeArt® AI Eye Screening System
The EyeArt Eye Screening System provides fully automated DR screening,
including imaging, grading for DR in accordance with internationally
recognized standards, and reporting, in a single office visit, enabling
quick and accurate identification of patients with referable DR during a
diabetic patient’s regular exam. Once the patient’s fundus images have
been captured and submitted to the EyeArt System, the DR screening
results are available to view and export to a PDF report in less than 60
seconds. The EyeArt System was developed with funding from the U.S.
National Institutes of Health (NIH) and is validated by the U.K.
National Health Service (NHS).
The EyeArt System has CE marking as a class 2a medical device in the
European Union and a Health Canada license. In the U.S., the EyeArt
System is limited by federal law to investigational use. EyeArt is
designed to be General Data Protection Regulation (GDPR) and HIPAA
(Health Insurance Portability and Accountability Act of 1996) compliant.
About Diabetic Retinopathy (DR)
DR is a complication of diabetes caused by damage to the blood vessels
of the light-sensitive tissue at the back of the eye (retina). It is a
silently progressing disease that at first may cause no symptoms or only
mild vision problems. Eventually, it can cause blindness. The condition
can develop in anyone who has type 1 or type 2 diabetes.2 It
is estimated that one-third of all patients with diabetes will develop
DR,3 making it the leading cause of vision loss in
While DR screening is recommended for all diabetic patients, less than
half get screened annually5 even in the developed world.
Since diabetic patients outnumber ophthalmologists by 1,600 to 1 in the
U.S.,6 there are just not enough eye care specialists to meet
the DR screening needs of the growing diabetic population. Even for
those receiving their annual screening, ophthalmology appointment wait
times for DR screening can be weeks or even months.
About Eyenuk Inc.
Eyenuk Inc. is a global artificial intelligence (AI) medical technology
and services company and the leader in real-world AI Eye Screening™ for
autonomous disease detection and AI Predictive Biomarkers™ for risk
assessment and disease surveillance. Eyenuk is on a mission to screen
every eye in the world to ensure timely diagnosis of life- and
vision-threatening diseases, including diabetic retinopathy, glaucoma,
age-related macular degeneration, stroke risk, cardiovascular risk and
EyeArt is a registered trademark of Eyenuk Inc.
Lim, J, et al. Artificial intelligence screening for diabetic
retinopathy: analysis from a pivotal multi-center prospective clinical
trial. ARVO Imaging in the Eye Conference 2019. Vancouver, BC, Canada.
Yau JW, Rogers SL, Kawasaki R, et al. Global
prevalence and major risk factors of diabetic retinopathy. Diabetes
Care. 2012;35:556-64. doi: 10.2337/dc11-1909.
Prokofyeva E, Zrenner E. Epidemiology
of major eye diseases leading to blindness in Europe: a literature
review. Ophthalmic Res. 2012;47:171-188. doi:
Fitch, K et al. Longitudinal commercial claims–based cost analysis of
diabetic retinopathy screening patterns. Am Health Drug Benefits. 2015